Product Description
Mechanisms of Action: Vitamin K Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: France | Luxembourg
Approved Indications: None
Known Adverse Events: None
Company: Daiichi Sankyo
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Hemostatic Disorders|Blood Coagulation Disorders|Embolism and Thrombosis|Calcinosis|Kidney Diseases|Atrial Fibrillation|Venous Thrombosis|Pulmonary Embolism|Vascular Calcification
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02800941 |
HEMA-HTP | N/A |
Completed |
Hypertension, Pulmonary |
2022-09-13 |
2024-06-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02286414 |
PRESAGE-ACO | N/A |
Completed |
Atrial Fibrillation |
2021-11-01 |
2022-03-30 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
ACTRN12618001078246p |
201911037RIND | N/A |
Not yet recruiting |
Cholelithiasis|Intestinal Diseases|Pain, Postoperative |
2018-07-16 |
|||
2024-512685-33-00 |
PHRC-N/2020/BL-01 | P3 |
Recruiting |
Unknown |
2026-11-30 |
2025-05-02 |
Treatments |
|
2016-003398-16 |
AVKDIAL | P4 |
Terminated |
Kidney Diseases|Atrial Fibrillation |
2023-08-10 |
|||
NCT02161965 |
VICTORIA | P4 |
Completed |
Atrial Fibrillation|Calcinosis|Vascular Calcification|Pulmonary Embolism|Embolism and Thrombosis|Venous Thrombosis |
2016-12-31 |
2019-11-08 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT00966290 |
COMPARE | P4 |
Completed |
Hemostatic Disorders|Blood Coagulation Disorders |
2006-12-01 |
2019-03-19 |
Treatments |